381 related articles for article (PubMed ID: 26349824)
21. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).
Sader HS; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202
[TBL] [Abstract][Full Text] [Related]
22. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and antibacterial activity of demethylvancomycin analogues against drug-resistant bacteria.
Chang J; Zhang SJ; Jiang YW; Xu L; Yu JM; Zhou WJ; Sun X
ChemMedChem; 2013 Jun; 8(6):976-84. PubMed ID: 23576378
[TBL] [Abstract][Full Text] [Related]
24. Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms.
Mendes RE; Huband MD; Streit JM; Castanheira M; Flamm RK
Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115054. PubMed ID: 32376058
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.
Xiao M; Huang JJ; Zhang G; Yang WH; Kong F; Kudinha T; Xu YC
BMC Microbiol; 2020 Nov; 20(1):350. PubMed ID: 33198626
[TBL] [Abstract][Full Text] [Related]
27. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
28. Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.
Felmingham D
J Chemother; 2005 Aug; 17 Suppl 1():5-11. PubMed ID: 16285353
[TBL] [Abstract][Full Text] [Related]
29. Purification and characterization of actinomycins from Streptomyces strain M7 active against methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus.
Sharma M; Manhas RK
BMC Microbiol; 2019 Feb; 19(1):44. PubMed ID: 30782119
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of isatin-β-thiosemicarbazones as novel agents against antibiotic-resistant Gram-positive bacterial species.
Zhang XM; Guo H; Li ZS; Song FH; Wang WM; Dai HQ; Zhang LX; Wang JG
Eur J Med Chem; 2015 Aug; 101():419-30. PubMed ID: 26185006
[TBL] [Abstract][Full Text] [Related]
31. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Tanaka SK; Steenbergen J; Villano S
Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981
[TBL] [Abstract][Full Text] [Related]
32. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
Dowzicky MJ; Chmelařová E
Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.
Draper MP; Weir S; Macone A; Donatelli J; Trieber CA; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(3):1279-83. PubMed ID: 24041885
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018.
Dong D; Zheng Y; Chen Q; Guo Y; Yang Y; Wu S; Zhu D; Deng D; Bradford PA; Reinhart H; Hu F
Eur J Clin Microbiol Infect Dis; 2020 Aug; 39(8):1559-1572. PubMed ID: 32356026
[TBL] [Abstract][Full Text] [Related]
35. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.
Jones RN; Stilwell MG; Wilson ML; Mendes RE
Diagn Microbiol Infect Dis; 2013 May; 76(1):69-72. PubMed ID: 23490012
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic activity of the lantibiotic MU1140.
Ghobrial OG; Derendorf H; Hillman JD
Int J Antimicrob Agents; 2009 Jan; 33(1):70-4. PubMed ID: 18835136
[TBL] [Abstract][Full Text] [Related]
37. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
38. The glycylcyclines: a comparative review with the tetracyclines.
Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
[TBL] [Abstract][Full Text] [Related]
39. N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci.
Goldstein FW; Kitzis MD; Acar JF
Antimicrob Agents Chemother; 1994 Sep; 38(9):2218-20. PubMed ID: 7811053
[TBL] [Abstract][Full Text] [Related]
40. Activity of glycylcyclines CL 329998 and CL 331002 against minocycline-resistant and other strains of methicillin-resistant Staphylococcus aureus.
Hamilton-Miller JM; Shah S
J Antimicrob Chemother; 1996 Jun; 37(6):1171-5. PubMed ID: 8836820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
